We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Pipeline

:

Driving new boundaries in drug development

Identifying and investigating new treatments to improve patient outcomes

Our pipeline

We are building a rich pipeline of assets in four main therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases. Our most advanced assets entered development in 2015 with first proof of concepts scheduled for readout by 2019.

Download Pipeline PDF

Presentations and publications

KY1044 anti-ICOS antibody at SITC

Kymab's data at the November 2017 Society for Immunotherapy of Cancer meeting on its lead immuno-oncology antibody KY1044, showing strong potential for inhibiting tumour growth

View the poster

T-cell:tumour cell antibody assay

2017 British Society for Immunology Congress poster showing that T-cells generated by Kymab's co-culture system can provide a suitable setting for evaluation of potential patient responses to immunotherapy

View the poster

Screening for anti-human PD-L1 antibodies

At the 2017 British Society for Immunology Congress, Kymab's team describe a cell-based, in vitro screening cascade to characterise anti-human PD-L 1 antibodies, identifying a lead clone, KY1003, that has the attributes of a clinically relevant PD-L1 antibody

View the poster

Modelling T-cells in tumour microenvironments

The Kymab team developed a "tumour-educated" T-cell killing assay for predictive in vitro assessment of anti-PD-L1 antibodies: data presented at the 2017 British Society for Immunology Congress shows how KY1003 can revert T-cell exhaustion in in vitro models.

View the poster

KY1044 anti-ICOS activity

At the April 2018 American Association for Cancer Research Annual meeting, Kymab's team show that combining immune checkpoint blockers with the anti-ICOS KY1044 antibody results in a strong tumour response, warranting the assessment of KY1044 in cancer patients in a clinical trial

View the poster

KY1055: ICOS/PD-L1 bispecific antibody

Kymab's data reports that KY1055, a novel ICOS/PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo: the results, presented at the April 2018 American Association for Cancer Research Annual meeting, support development of KY1055 for the treatment of solid tumours

View the poster

Kymouse has full human antibody system

Published in Nature Biotechnology in March 2014, the paper by Kymab scientists describes the development of Kymouse, which is able to produce an enormous range of human antibodies that can be developed as potent drugs to treat diseases such as cancer, autoimmune and infectious diseases.

Read the publication

KY1005 impressive in acute GVHD model

Kymab and Seattle Children’s Research Institute publish impressive results in Science Translational Medicine using KY1005 in a model of acute Graft-versus-Host Disease (aGVHD), suggesting an important role in blood-system transplants, such as in the treatment of leukaemia.

Read the publication

Our Kymouse™ platform can deliver the finest novel therapeutic antibodies

Learn more